nadofaragene firadenovec + celecoxib + gemcitabine

This is a **combination therapy** consisting of nadofaragene firadenovec, celecoxib, and gemcitabine, potentially designed for the treatment of cancers, most notably bladder cancer. - **Nadofaragene firadenovec** is a non-replicating adenoviral vector-based gene therapy delivering interferon alfa-2b to the bladder epithelium, promoting apoptosis and anti-tumor responses via local gene expression[4][2][7]. - **Celecoxib** is a selective COX-2 inhibitor (NSAID) with anti-inflammatory and anti-tumor activity, sometimes used as adjunct cancer therapy due to its ability to inhibit tumor growth and angiogenesis (no direct source in your set, but established biomedical consensus). - **Gemcitabine** is a pyrimidine nucleoside antimetabolite that inhibits DNA synthesis, causing cell death, and is widely used in the treatment of several solid tumors, including bladder, lung, breast, pancreatic, and ovarian cancers[3][6]. The rationale behind such a combination could involve leveraging synergistic anti-tumor mechanisms: immunomodulation/gene therapy (nadofaragene firadenovec), inhibition of inflammation/COX-2 pathway (celecoxib), and direct cytotoxicity to malignant cells (gemcitabine).

Other names

nadofaragene firadenovec-vncgnadofaragene firadenoveccelecoxibgemcitabine